| Old Articles: <Older 1331-1340 Newer> |
|---|
 |
The Motley Fool
July 29, 2004
Brian Gorman |
Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look.   |
The Motley Fool
July 28, 2004
Brian Gorman |
Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge. |
Inc.
August 2004
Jonathan Black |
Always the Optimist Lessons in perseverance from Darlene Ryan, owner of the drugmaker PharmaFab. It takes more than a ding to shake Darlene. |
The Motley Fool
July 27, 2004
Brian Gorman |
Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans. |
The Motley Fool
July 27, 2004
Charly Travers |
Cash Concerns at Vertex New royalties might not help offset losses at the pharmaceutical, so it's time to look at the drug pipeline. |
The Motley Fool
July 27, 2004
Brian Gorman |
Omnicare in a "Rough Patch"? Missed earnings expectations raise questions about its NeighborCare purchase. |
The Motley Fool
July 27, 2004
Tom Taulli |
What's at Stake in Managed Care Merger? Anthem and WellPoint's union may face a fight against California. |
The Motley Fool
July 26, 2004
W.D. Crotty |
Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
July 22, 2004
Charly Travers |
A Millennium Pharmaceuticals Mix Sales for one drug are encouraging, while sales for another one are declining. |
| <Older 1331-1340 Newer> Return to current articles. |
